- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
Editas Medicine is a biotechnology business based in the US. Editas Medicine shares (EDIT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.23 – an increase of 12.63% over the previous week. Editas Medicine employs 265 staff and has a trailing 12-month revenue of around $61.8 million.
Our top picks for where to buy Editas Medicine stock
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Complimentary access to a financial planner
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
How to buy Editas Medicine stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – EDIT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Editas Medicine stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Editas Medicine stock price (NASDAQ: EDIT)
Use our graph to track the performance of EDIT stocks over time.Editas Medicine shares at a glance
Latest market close | $2.23 |
---|---|
52-week range | $1.95 - $11.58 |
50-day moving average | $3.01 |
200-day moving average | $5.02 |
Wall St. target price | $8.15 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-2.55 |
Is it a good time to buy Editas Medicine stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Editas Medicine price performance over time
Historical closes compared with the close of $2.14 from 2024-12-06
1 week (2024-12-03) | 8.08% |
---|---|
1 month (2024-11-11) | -35.15% |
3 months (2024-09-10) | -43.24% |
6 months (2024-06-10) | -59.77% |
1 year (2023-12-08) | -79.64% |
---|---|
2 years (2022-12-09) | -77.35% |
3 years (2021-12-10) | 29.01 |
5 years (2019-12-10) | 30.69 |
Editas Medicine financials
Revenue TTM | $61.8 million |
---|---|
Gross profit TTM | $-155,246,000 |
Return on assets TTM | -34.32% |
Return on equity TTM | -78.56% |
Profit margin | 0% |
Book value | $2.13 |
Market Capitalization | $164.3 million |
TTM: trailing 12 months
Editas Medicine share dividends
We're not expecting Editas Medicine to pay a dividend over the next 12 months.
Editas Medicine share price volatility
Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $1.95 up to $11.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Editas Medicine's is 2.006. This would suggest that Editas Medicine's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Editas Medicine overview
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.
Frequently asked questions
nullWhat percentage of Editas Medicine is owned by insiders or institutions?
Currently 0.321% of Editas Medicine shares are held by insiders and 71.08% by institutions. How many people work for Editas Medicine?
Latest data suggests 265 work at Editas Medicine. When does the fiscal year end for Editas Medicine?
Editas Medicine's fiscal year ends in December. Where is Editas Medicine based?
Editas Medicine's address is: 11 Hurley Street, Cambridge, MA, United States, 02141 What is Editas Medicine's ISIN number?
Editas Medicine's international securities identification number is: US28106W1036 What is Editas Medicine's CUSIP number?
Editas Medicine's Committee on Uniform Securities Identification Procedures number is: 28106W103
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask a question